Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.
Epistemonikos ID: 4993916a704f006170ae525ab7fcd37fcbc17ad7
First added on: May 20, 2024